Linero Tablet contains Linagliptin 5mg, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Linagliptin works by enhancing the levels of incretin hormones, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner, thereby improving glycemic control. This medication is typically prescribed as an adjunct to diet and exercise to improve blood sugar levels in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. Linero Tablet offers the advantage of once-daily oral administration with minimal risk of hypoglycemia due to its glucose-dependent mechanism of action. It is well tolerated, with a safety profile characterized by a low incidence of adverse effects, including nasopharyngitis, headache, and gastrointestinal disturbances. Linagliptin does not require dose adjustment in patients with renal impairment, making it suitable for a broad patient population. Regular monitoring of blood glucose and HbA1c levels is recommended to assess therapeutic efficacy. Linero Tablet should be used under medical supervision, with attention to potential drug interactions and contraindications.